Tech Company Financing Transactions
Intellia Therapeutics Funding Round
Intellia Therapeutics, operating out of Cambridge, received $70 million from OrbiMed, EcoR1 Capital Management and Fidelity Management & Research Company.
Transaction Overview
Company Name
Announced On
9/1/2015
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the proceeds to accelerate the development of its pipeline, expand its platforms for gene editing and delivery, as well as to continue to strengthen its leading intellectual property portfolio.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
40 Erie St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
Intellia (NASDAQ: NTLA) is a leading gene editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Leonard
Chief Financial Officer
Glenn Goddard
Vice President
Eliana Clark
VP - Bus. Development
Christine Foster
VP - General Counsel
Nishla Keiser
VP - General Counsel
Jose Rivera
Browse more venture capital transactions:
Prev: 9/1/2015: misterbnb venture capital transaction
Next: 9/2/2015: Infinite Analytics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs